Willingness to pay for adverse drug event regulatory actions

PharmacoEconomics

Volumn 29, Issue 11, 2011, Pages 963-975

  Bouvy, Jacoline ^a,b   Weemers, Just ^a   Schellekens, Huub ^b   Koopmanschap, Marc ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adverse drug reactions; Contingent valuation; Epoetin alfa; Pure red cell aplasia; Willingness to pay.

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; COMPENSATION; FEMALE; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; NETHERLANDS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; TOBIT MODEL; WILLINGNESS TO PAY;

ADULT; ATTITUDE TO HEALTH; DATA COLLECTION; DIALYSIS; DRUG AND NARCOTIC CONTROL; DRUG COSTS; ERYTHROPOIETIN; FEMALE; HEALTH STATUS; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; QUALITY OF LIFE; RECOMBINANT PROTEINS; RISK REDUCTION BEHAVIOR;

EID: 80054093763     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11539860-000000000-00000     Document Type: Article

References (51)

1. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008; 83 (2): 227-30
2. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287 (17): 2215-20 (Pubitemid 34441937)
3. European Medicines Agency. CPMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urinederived medicinal products. London: EMA, 2004 [online]. Available from URL: http://www.ema.europa.eu/ema/pages/includes/ document/open-document.jsp?webContentId=WC500003770 [Accessed 2011 May 9]
4. DiMasi J, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85 (Pubitemid 36279392)
5. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346 (7): 469-75 (Pubitemid 34441737)
6. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res ClHa 2005; 18 (3): 473-80 (Pubitemid 40425360)
7. Macdougall I. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transpl 2005; 20 Suppl. 4: 9-15
8. Bennet C, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-8 (Pubitemid 39288166)
9. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Epoetin alpha formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-53 (Pubitemid 41623396)
10. van de Ven WPMM, Schut FT. Universal mandatory health insurance in the Netherlands: a model for the United States? Health Aff 2008; 27 (3): 771-881
11. Belastingdienst. Hoe hoog is de inkomensafhankelijke bijdrage voor de Zorgverzekeringswet? [online]. Available from URL: http://www.rijksoverheid.nl/ documenten-en-public aties/vragen-en-antwoorden/hoe-hoog-is-de-inkomensafh ankelijke-bijdrage-voor-de-zorgverzekeringswet.html [Accessed 2010 Jun 23]
12. Barsky RB, Juster FT, Kimball MS, et al. Preference parameters and behavioral heterogeneity: an experimental approach in the health and retirement study. Q J Econ 1997; 112 (2): 537-79 (Pubitemid 127344013)
13. Dave D, Saffer H. Alcohol demand and risk preference. J Econ Psychol 2008; 29 (6): 810-31
14. Ryan M, Ratcliffe J, Tucker J. Using willingness to pay to value alternative models of antenatal care. Soc Sci Med 1997; 44 (3): 371-80 (Pubitemid 27032455)
15. Donaldson C, Shackley P, Abdalla M. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 1998; 6 (2): 145-59 (Pubitemid 27199140)
16. Gyldmark M, Morrison G. Demand for heath care in Denmark: results of a national sample survey using contingent valuation. Soc Sci Med 2001; 53: 1023-36 (Pubitemid 32737543)
17. Johannesson M, Johansson PO, Bengt K, et al. Willingness to pay for antihypertensive therapy: further results. J Health Econ 1993; 12 (1): 95-108 (Pubitemid 23183897)
18. Hammitt J, Graham J. WTP for health protection: inadequate sensitivity to probability? J Risk Uncertain 1999; 8: 33-62
19. Nocera S, Bonato D, Telser H. The contingency of contingent valuation: how much are people willing to payagainst Alzheimer's disease? Int J Health Care Finance Econ 2002; 2 (3): 219-40
20. Smith RD. Construction of the contingent valuation market in health care: a critical assessment. Health Econ 2003; 12 (8): 609-28 (Pubitemid 37038358)
21. Zhai G, Suzuki T. Effect of risk representation and scope on WTP for reduced risks: evidence from Tokyo Bay, Japan. Risk Anal 2008; 28 (2): 513-22 (Pubitemid 351550601)
22. Lamers LM, Stalmeier PFM, McDonnell J, et al. Measuring the quality of life in economic evaluations: the Dutch EQ- 5D tariff [in Dutch]. Nederlands Tijdschrift Geneeskunde 2005; 149 (28): 1574-8 (Pubitemid 40978328)
23. Hofstede G, Hofstede GJ. Cultures and organizations: software of the mind. Intercultural cooperation and its importance for survival. New York: McGraw-Hill, 2005
24. Wagner TH, Hu T-W, Dueñas GV, et al. Willingness to pay for mammography: item development and testing among five ethnic groups. Health Policy 2000; 53: 105-21 (Pubitemid 30665399)
25. Donaldson C, Jones AM, Mapp TJ, et al. Limited dependent variables in willingness to pay studies: applications in health care. Appl Econ 1998; 30: 667-77 (Pubitemid 128768999)
26. Kealy MJ, Turner RW. A test of the equality of closedended and open-ended contingent valuations. Am J Agr Econ 1993; 75: 321-31
27. Roncek D. Learning more from tobit coefficients: extending a comparative analysis of political protest. Am Sociol Rev 1992; 57 (4): 503-7
28. Wooldridge JM. Introductory econometrics: a modern approach. 4th ed. Cincinnati (OH): South-Western College Publishing, 2009
29. Kahneman D, Knetsch J. Valuing public goods: the purchase of moral satisfaction. J Environ Econ Manage 1992; 22: 57-70
30. Baron J, Greene J. Determinants of insensitivity to quantity in valuation of public goods: contribution, warm glow, budget constraints, availability, and prominence. J Exp Psychol Appl 1996; 2 (2): 107-25 (Pubitemid 126449988)
31. Bleichrodt H, Eeckhoudt L. Willingness to pay for reductions in health risks when probabilities are distorted. Health Econ 2006; 15: 211-4 (Pubitemid 43193348)
32. Werner P, Vered I. Women's willingness to pay out-ofpocket for drug treatment for osteoporosis before and after the enactment of regulations providing public funding: evidence from a natural experiment in Israel. Osteoporos Int 2002 Mar; 13 (3): 228-34 (Pubitemid 34408190)
33. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, et al. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Brit J Dermatol 2003; 148: 1153-60 (Pubitemid 36819214)
34. Boonen A, Severens JL, van Tubergen A, et al. Willingness of patients with ankylosing spondylitis to pay for inpatient treatment is influenced by the treatment environment and expectations of improvement. Ann Rheum Dis 2005; 64 (11): 1650-2 (Pubitemid 41532053)
35. Neumann P, Johannesson M. The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care 1994; 32 (7): 686-99
36. Wordsworth S, Ryan M, Waugh N. Costs and benefits of cervical screening IV: valuation by women of the cervical screening programme. Cytopathology 2001; 12 (6): 367-76 (Pubitemid 35300617)
37. Marra CA, Frighetto L, Goodfellow AF, et al. Willingness to pay to assess patient preferences for therapy in a Canadian setting. BMC Health Serv Res 2005; 5: 43
38. Pinto-Prades J, Farreras V, de Bobadilla J. Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone. Eur J Health Econ 2008; 9: 69-78
39. Liu JT, Tsou MW, Hammitt JK. Willingness to pay for weight-control treatment. Health Policy 2009; 91 (2): 211-8
40. Liljas B, Blumenschein K. On hypothetical bias and calibration in cost-benefit studies. Health Policy 2000; 52 (1): 53-70 (Pubitemid 30160762)
41. Blumenschein K, Johannesson M, Yokoyama KY, et al. Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. J Health Econ 2001; 20: 441-57 (Pubitemid 32331842)
42. van Exel NJA, Brouwer WBF, van den Berg B, et al. With a little help from an anchor: discussion and evidence of anchoring effects in contingent valuation. J Socio-Econ 2006; 35: 836-53 (Pubitemid 44283779)
43. Samnaliev M, Stevens TH, More T. A comparison of alternative certainty calibration techniques in contingent valuation. Ecolog Econ 2006; 57 (3): 507-19
44. Kosenius AK. Causes of response uncertainty and its implications forWTP estimation in choice experiment.Helsinki: University of Helsinki, Department of Economics and Management, 2009. Discussion paper no. 29
45. Johannesson M, Jonsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279-96
46. Rollins K, Lyke A. The case for diminishing marginal existence values. J Environ Econ Manag 1998; 36: 324-44 (Pubitemid 28537089)
47. Wagstaff A, van Doorslaer E. Equity in health care finance and delivery. In:CulyerAJ, Newhouse JP, editors. Handbook of health economics. Volume IB. Amsterdam: Elsevier, 2000: 1803-62
48. Schut E, van Doorslaer E. Demand for health care. In: Schut E, Rutten F, editors. Economics of health care. Vol 3 [in Dutch]. Maarssen: Elsevier Gezondheidszorg, 2009: 83-128
49. Jones-Lee M. Altruism and the value of other people's safety. J Risk Uncertain 1991; 4: 213-9
50. Jones-Lee M. Paternalistic altruism and the value of statistical life. Econ J 1992; 102 (410): 80-90
51. Jacobsson F, Carstensen J, Borgquist L. Caring externalities in health economic evaluation: how are they related to severity of illness? Health Policy 2005; 73 (2): 172-82. (Pubitemid 40835900)